October 26th 2024
FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.
October 15th 2024
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...
November 16, 2024
Register Now!
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Practice Connections™: Optimize the Diagnosis and Treatment of HER2-Positive Colorectal Cancer
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer
An immunotherapy combination that adds the interleukin-10 agonist AM0010 to FOLFOX chemotherapy will be evaluated in a phase III trial for patients with metastatic pancreatic cancer that could introduce a new modality to the treatment paradigm for the malignancy.
Dr. Daver on Immune Checkpoint Pathways in AML
December 28th 2016Naval Daver, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses research evaluating different immune checkpoint pathways in patients with acute myeloid leukemia.
Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment
December 28th 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.
Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma
December 27th 2016Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.
Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer
December 23rd 2016Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.
Dr. Weber on Risk and Benefits With Immunotherapy Combos in Melanoma
December 23rd 2016Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the risks and benefits of combination immunotherapy as treatment for patients with melanoma.
Expert Discusses Challenges With Non-Driver Lung Adenocarcinoma
December 23rd 2016Molecular testing is done for patients with non–small cell lung cancer to determine what genetic abnormalities are present. If a common-enough mutation is detected—such as EGFR or ALK—then patients are able to receive a targeted agent matched to that driver.
Dr. Hamid on Immunotherapy Approaches in Melanoma
December 22nd 2016Omid Hamid, MD, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, discusses different immunotherapy approaches that oncologists are currently exploring in melanoma.